background although previous randomized doubleblind placebocontrolled trials reported the efficacy of omega3 fatty acid supplements in the secondary prevention of cardiovascular disease cvd the evidence remains inconclusiveusing a metaanalysis we investigated the efficacy of eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of cvdmethods we searched pubmed embase and the cochrane library in april 2011two of us independently reviewed and selected eligible randomized controlled trialsresults of 1007 articles retrieved 14 randomized doubleblind placebocontrolled trials involving 20 485 patients with a history of cvd were included in the final analysessupplementation with omega3 fatty acids did not reduce the risk of overall cardiovascular events relative risk 099 95 ci 089109 allcause mortality sudden cardiac death myocardial infarction congestive heart failure or transient ischemic attack and strokethere was a small reduction in cardiovascular death relative risk 091 95 ci 084099 which disappeared when we excluded a study with major methodological problemsfurthermore no significant preventive effect was observed in subgroup analyses by the following country location inland or coastal geographic area history of cvd concomitant medication use type of placebo material in the trial methodological quality of the trial duration of treatment dosage of eicosapentaenoic acid or docosahexaenoic acid or use of fish oil supplementation only as treatmentconclusion our metaanalysis showed insufficient evidence of a secondary preventive effect of omega3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease